Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer-Reference-Cited by-同舟云学术

Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer

Published:2020-03 Issue:3 Volume:43 Page:467-475
ISSN:1015-9584
Container-title:Asian Journal of Surgery
language:en
Short-container-title:Asian Journal of Surgery

Author:

Park Young Ryul,Lee Jeeyeon,Jung Jin Hyang,Kim Wan Wook,Park Chan Sub,Lee Ryu Kyung,Chae Yee Soo,Lee Soo Jung,Park Ji-Young,Park Jee Young,Park Ho Yong

Funder

National Research Foundation of Korea

Korea government

National R&D Program for Cancer Control

Ministry of Health and Welfare, Republic of Korea

Korea Health Industry Development Institute

Ministry of Health & Welfare, Republic of Korea

Publisher

Elsevier BV

Subject

Surgery

Reference27 articles.

1. Biological subtypes of breast cancer: prognostic and therapeutic implications;Yersal;World J Clin Oncol,2014

2. Biological subtypes of triple-negative breast cancer;Hubalek;Breast Care (Basel),2017

3. Triple positive breast cancer: a distinct subtype?;Vici;Cancer Treat Rev,2015

4. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going;Omarini;Cancer Manag Res,2018

5. Recent advances in the neoadjuvant treatment of breast cancer;Rubovszky;J Breast Cancer,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen Receptor-negative Ductal CarcinomaIn Situ(DCIS) of the Breast – an Institutional Review of Outcomes;Anticancer Research;2023-08-30

2. Real-Life Data of Neoadjuvant Chemotherapy in Breast Cancer: Aegean Region Experience;European Journal of Therapeutics;2023-04-05

3. Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors;Scientific Reports;2022-03-18

4. Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development;Cancers;2021-09-24

5. Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin;Frontiers in Oncology;2021-02-09